Original article| Volume 116, ISSUE 3, SUPPLEMENT 1, 17-22, February 02, 2004

Treatment of patients with severe insulin deficiency

what we have learned over the past 2 years
  • Irl B Hirsch
    Requests for reprints should be addressed to Irl B. Hirsch, MD, University of Washington School of Medicine, 1959 NE Pacific, UW Mailbox 356176, Seattle, Washington 98195-6176, USA.
    Diabetes Care Center and the Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Search for articles by this author


      The initial injection in 1922 of a pancreatic extract, or insulin as it came to be known, into a patient with diabetes mellitus has since been followed by the successive introduction of longer-acting insulins, more highly purified insulins, and insulins that have been modified to more closely match insulin activity to patients' physiologic requirements. The recently introduced rapid-acting insulin analogues lispro and aspart and the long-acting analogue glargine are further refinements of insulin therapy. Current treatment strategies for severe insulin deficiency are based on the need to provide 2 components of insulin replacement: basal and postprandial. Rapid-acting insulin has been shown to provide superior postprandial glucose control compared with regular insulin. Truly effective control of basal insulin has been achieved by the introduction of the insulin pump in the 1980s and insulin glargine in 2001. Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Clinical experience is providing many insights into how basal and prandial components of insulin therapy can be best combined, although evidence from controlled trials will take some years to accumulate. Experience and observations since 2001 indicate that insulin therapy should be introduced earlier in patients with type 2 diabetes to control blood glucose levels. More importantly, the greatest benefit of insulin glargine has been to change positively the way physicians and patients think about insulin therapy. Newer insulin analogues, improved devices for home glucose monitoring, and pulmonary inhaled insulin are other innovations that promise improvement of hemoglobin A1c levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bliss M.
        The Discovery of Insulin.
        University of Chicago Press, Chicago, IL1984
        • Cammidge P.J.
        • Cairns Forsyth J.A.
        • Howard H.A.H.
        Drugs in the treatment of diabetes mellitus.
        Lancet. 1922; 200: 1324-1327
        • The Diabetes Control and Complications Trial Research Group
        The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
        N Engl J Med. 1993; 329: 977-986
        • UK Prospective Diabetes Study Group
        UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes.
        Diabetes. 1995; 44: 1249-1258
        • Hayward R.A.
        • Manning W.G.
        • Kaplan S.H.
        • Wagner E.H.
        • Greenfield S.
        Starting insulin therapy in patients with type 2 diabetes.
        JAMA. 1997; 278: 1663-1669
        • Home P.D.
        • Lindholm A.
        • Hylleberg B.
        • Round P.
        • UK Insulin Aspart Study Group
        Improved glycemic control with insulin aspart.
        Diabetes Care. 1998; 21: 1904-1909
        • Rossetti P.
        • Pampanelli S.
        • Fanelli C.
        • et al.
        Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime.
        Diabetes Care. 2003; 26: 1490-1496
        • Zinman B.
        • Tildesley H.
        • Chiasson J.L.
        • Tsui E.
        • Strack T.
        Insulin lispro in CSII.
        Diabetes. 1997; 46: 440-443
        • Mudaliar S.R.
        • Lindberg F.A.
        • Joyce M.
        • et al.
        Insulin aspart (B28 asp-insulin).
        Diabetes Care. 1999; 22: 1501-1506
        • Lalli C.
        • Ciofetta M.
        • Del Sindaco P.
        • et al.
        Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
        Diabetes Care. 1999; 22: 468-477
        • Kaufman F.R.
        • Gibson L.C.
        • Halvorson M.
        • Carpenter S.
        • Fisher L.K.
        • Pitukcheewanont P.
        A pilot study of the continuous glucose monitoring system.
        Diabetes Care. 2001; 24: 2030-2034
        • Kelly J.L.
        • Hirsch I.B.
        • Trence D.L.
        Rapid decrease in clinically significant hypoglycemia with insulin glargine.
        Diabetes. 2002; 51 (Abstract 497-P): A123
        • DeWitt D.E.
        • Hirsch I.B.
        Outpatient insulin therapy in type 1 and type 2 diabetes mellitus.
        JAMA. 2003; 289: 2254-2264